Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
- Conditions
- Interventions
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 5
- Registration Number
- NCT03393741
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 256
- Registration Number
- NCT03386721
- Locations
- 🇫🇷
ICM; Medecine B3, Montpellier cedex 5, France
🇬🇧Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom
🇹🇷Adana Baskent University Hospital; Medical Oncology, Adana, Turkey
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 200
- Registration Number
- NCT03345810
- Locations
- 🇩🇪
Klinikum Darmstadt, Darmstadt, Germany
🇩🇪DRK-Kliniken Berlin Mitte, Berlin-Mitte, Germany
🇩🇪Gesundheitszentrum St. Marien GmbH, Amberg, Germany
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 105
- Registration Number
- NCT03321981
- Locations
- 🇵🇹
Champalimaud Clinical Centre, Lisbon, Portugal
🇵🇹Hopistal San Antonio, Porto, Portugal
🇪🇸Instituto Valenciano de Oncologia, Valencia, Spain
Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Tao OUYANG
- Target Recruit Count
- 304
- Registration Number
- NCT03270007
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 66
- Registration Number
- NCT03254654
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
PemVin vs Vin in Previously Treated Metastatic Breast Cancer
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 125
- Registration Number
- NCT03242616
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 453
- Registration Number
- NCT03191786
- Locations
- 🇩🇪
LungenClinic Großhansdorf GmbH; Klinische Forschung, Großhansdorf, Germany
🇦🇷Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina
🇦🇷Hospital Privado de Comunidad, Mar del Plata, Argentina
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 36
- Registration Number
- NCT03188159
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Australia
Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 21
- Registration Number
- NCT03161054
- Locations
- 🇮🇹
A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy
🇮🇹Ospedale di Castelfranco Veneto - Ematologia, Castelfranco Veneto, Italy
🇮🇹Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS c/o CORE (II piano) - Ematologia, Reggio Emilia, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.